Influencing Factors for Erectile Dysfunction of Young Adults with No Response to PDE5i

被引:0
|
作者
Jin Wang
Yan-li Wang
Yao He
Sen Li
You-peng Zhang
Yong-biao Cheng
Jia-lun Guo
Lin Sun
Yu Xin
Yong Tang
Zhao-hui Zhu
Han-qing Zeng
机构
[1] Huazhong University of Science and Technology,Department of Urology, Union Hospital, Tongji Medical College
来源
Current Medical Science | 2021年 / 41卷
关键词
erectile dysfunction; PDE5 inhibitors; influencing factor;
D O I
暂无
中图分类号
学科分类号
摘要
Erectile dysfunction (ED) is a common male disorder. Although orally-administered phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are now recognized as the primary pharmacological treatment method for ED, 20%–30% of the patients treated with PDE5 inhibitors exhibit no significant effects. This study aims to investigate the influencing factors of ED in young adults with no response to PDE5 inhibitors. ED patients who would take PDE5 inhibitors were included and investigated with a questionnaire. Patients with no response to PDE5 inhibitors (tadalafil and sildenafil) served as study group, and those with response to PDE5 inhibitors as control group. Then Chi square test and logistic regression analysis were applied to find the potential influencing factors. In total, 378 ED patients were included. Ninety-three (24.6%) cases were non-responsive to PDE5 inhibitors, and the remaining 285 (75.4%) responded to PDE5 inhibitors. In multiple logistic regression analysis, we found that history of drinking (OR=3.152; 95%CI 1.672–6.975), spousal noncooperation (OR=2.994; 95%CI 1.589–5.638), number of fixed sex partners (OR=0.358; 95%CI 0.132–0.651), duration of ED (OR=3.356; 95%CI 1.352–8.333), and depression (OR=3.689; 95%CI 1.579–8.979) could be the influencing factors for ED patients’ non-response to PDE5 inhibitors. In conclusion, history of drinking, spousal noncooperation, number of fixed sex partner, long duration of ED, and depression could be the influencing factors for ED patients’ non-response to PDE5 inhibitors. Patients and doctors should pay attention to these factors.
引用
收藏
页码:529 / 534
页数:5
相关论文
共 50 条
  • [1] Influencing Factors for Erectile Dysfunction of Young Adults with No Response to PDE5i
    Wang, Jin
    Wang, Yan-li
    He, Yao
    Li, Sen
    Zhang, You-peng
    Cheng, Yong-biao
    Guo, Jia-lun
    Sun, Lin
    Xin, Yu
    Tang, Yong
    Zhu, Zhao-hui
    Zeng, Han-qing
    CURRENT MEDICAL SCIENCE, 2021, 41 (03) : 529 - 534
  • [2] Correlates of PDE5i Use among Subjects with Erectile Dysfunction in Two Population-Based Surveys
    Travison, Thomas G.
    Hall, Susan A.
    Fisher, William A.
    Araujo, Andre B.
    Rosen, Raymond C.
    McKinlay, John B.
    Sand, Michael S.
    JOURNAL OF SEXUAL MEDICINE, 2011, 8 (11): : 3051 - 3057
  • [3] PRESERVATION OF BASELINE ERECTILE FUNCTION IN RADIOTHERAPY PATIENTS USING PDE5I
    Miranda, Eduardo P.
    Jenkins, Lawrence
    Nelson, Christian
    Zelefsky, Michael
    Mulhall, John P.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E644 - E644
  • [4] PRESERVATION OF BASELINE ERECTILE FUNCTION IN RADIOTHERAPY PATIENTS USING PDE5I
    Miranda, E. P.
    Jenkins, L.
    Nelson, C.
    Zelefsky, M.
    Mulhall, J.
    JOURNAL OF SEXUAL MEDICINE, 2018, 15 (07): : S156 - S156
  • [5] A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy
    Zhang, Ming
    Che, Ji-Zhong
    Liu, Yi-Dong
    Wang, Hong-Xiang
    Huang, Yan-Ping
    Lv, Xiang-Guo
    Liu, Wei
    Lu, Mu-Jun
    ASIAN JOURNAL OF ANDROLOGY, 2022, 24 (05) : 473 - +
  • [6] The effect of CPAP and PDE5i on erectile function in men with obstructive sleep apnea and erectile dysfunction: A systematic review and meta-analysis
    Li, Zeyan
    Fang, Zhiqing
    Xing, Naidong
    Zhu, Shiqin
    Fan, Yidong
    SLEEP MEDICINE REVIEWS, 2019, 48
  • [7] DAILY DOSING OF PDE5I IN LUTS
    Kim, Sae Woong
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 : 77 - 77
  • [8] The evaluation of lifelong erectile dysfunction with nocturnal penile tumescence rigican (NPTR) testing combined with a phosphodiesterase type 5 inhibitor (PDE5I)
    Raheem, A.
    Garaffa, G.
    Spillings, M.
    Kell, P.
    Minhas, S.
    Ralph, D. J. R.
    BJU INTERNATIONAL, 2008, 101 : 46 - 46
  • [9] PDE5i and melanoma—correlation is not causation
    Louise Stone
    Nature Reviews Urology, 2015, 12 (8) : 418 - 418
  • [10] IS PDE5I THE RIGHT TREATMENT FOR PE?
    Yang, Dae Yul
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 : 197 - 197